Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zemplar immune effects in birch pollen allergy
NCT02686827Phase 2Completed
- Start
- Oct 2015
- Primary completion
- Apr 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in allergic rhinitis (AR) and Rhinoconjunctivitis (RC) comparing Zemplar with Placebo (2 arms). Primary endpoint: Change in IL-10 production from baseline. Started Oct 2015; status: completed.
02
Drugs
paricalcitol
03
Conditions
allergic rhinitis (AR)Rhinoconjunctivitis (RC)
Beyond the preview
Go deeper on NCT02686827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02686827.